Bevacizumab的概述|专业知识背景|拓展阅读-小狗文献

Bevacizumab

肿瘤

关键词：肿瘤药物 单克隆IgG1抗体

词汇介绍

拓展阅读

解析

Bevacizumab

释义 n. 贝伐单抗

例句 Causes of death were predominantly due to lung cancer, but 14 patients in the bevacizumab group and 2 in the control group died as a result of drug toxicity. 尽管导致患者死亡的原因主要是肺癌，但是贝伐单抗组的14名患者以及对照组的2名患者却死于药物毒性。

概述

贝伐珠单抗（贝伐单抗、安维汀）是是瑞士罗氏制药旗下产品。是一种重组的人类单克隆IgG1抗体，可以抑制人血管内皮生长因子（VEGF）的生物活性。VEGF与其受体的相互作用导致血管生成的内皮细胞增殖和新血管形成，贝伐珠单抗可与血管内皮生长因子(VEGF)结合，阻碍VEGF与其受体在内皮细胞表面相互作用，从而减少微血管的生长并抑制肿瘤转移。贝伐单抗于2004年获得美国FDA的批准，是美国第一个获得批准上市的抑制肿瘤血管生成的药，主要用于转移性结直肠癌，晚期、转移性或复发性非小细胞肺癌的治疗。200

Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response复制标题

Nivolumab治疗化疗耐药宫颈癌: 外阴炎作为一种新的免疫相关不良事件的报告和持续完全应答的分子分析

发表时间：2019-10-31

影响因子：8.7

作者： Florence Baettig

期刊：J Immunother Cancer

Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in advanced cervical cancer has demonstrated a disease control rate of 68.4% with the immune checkpoint inhibitor nivolumab. By blocking immune checkpoints, immunotherapy puts the immune system into a state of hyper-activation that can cause immune-related adverse events. We present the clinical, pathological and molecular data of a patient with metastatic cervical cancer and progressive disease after second-line therapy. We report on the therapeutic response under third-line immunotherapy with nivolumab, the immune-related adverse events (IRAE), and their successful management.

译文

晚期宫颈癌的治疗选择有限，一线顺铂化疗和贝伐单抗治疗后复发的患者预后较差。最近在晚期宫颈癌中进行的II期研究表明，使用免疫检查点抑制剂nivolumab的疾病控制率为68.4％。通过阻断免疫检查点，免疫疗法使免疫系统进入过度激活状态，从而导致免疫相关的不良事件。我们介绍了二线治疗后转移性宫颈癌和进行性疾病患者的临床，病理和分子数据。我们报告了尼古拉单抗三线免疫治疗下的治疗反应，免疫相关不良事件（IRAE）及其成功治疗。